RT Journal Article
SR Electronic
T1 Tertiary Lymphoid Structure and CD8 T Cell Exclusion in Minimally Invasive Adenocarcinoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.03.20166991
DO 10.1101/2020.08.03.20166991
A1 Jin Wang
A1 Dongbo Jiang
A1 Xiaoqi Zheng
A1 Wang Li
A1 Tian Zhao
A1 Di Wang
A1 Huansha Yu
A1 Dongqing Sun
A1 Ziyi Li
A1 Jian Zhang
A1 Zhe Zhang
A1 Likun Hou
A1 Gening Jiang
A1 Fan Zhang
A1 Kun Yang
A1 Peng Zhang
YR 2020
UL http://medrxiv.org/content/early/2020/08/05/2020.08.03.20166991.abstract
AB Lung adenocarcinoma is the leading cause of cancer death. To characterize the tumor microenvironment (TME) of early-stage lung adenocarcinoma, we performed RNA-seq profiling on 59 pairs of minimally invasive adenocarcinoma (MIA) tumors and matched adjacent normal lung tissues from Chinese patients. We observed mucin over-expression and glycosylation, and altered cytokine-cytokine interactions in MIA tumors, which also had distinct adaptive immune TME of higher CD4+ T cell infiltration, higher plasma B cell activation, and lower CD8+ T cell infiltration. The high expression of markers for B cells, activated CD4 T cells, and follicular helper T (Tfh) cells in MIA implicated the formation of tertiary lymphoid structures (TLS), which were supported by two independent single-cell RNA-seq data. Multiplex immunohistochemistry (mIHC) staining of 22 MIA tumors validated TLS formation and revealed an enrichment of follicular regulatory T cells (Tfr) in TLS follicles, which may explain the lower CD8+ T cell infiltration and attenuated anti-tumor immunity in MIA.Significance We discovered a potential immunosuppressive phenotype in MIA mediated by follicular regulatory T cells (Tfr) in TLS formation, which could be a potential mechanism of CD8+ T cell exclusion. Our study demonstrated how integrating tumor transcriptome and pathology can characterize the TME and elucidate potential mechanisms of tumor immune evasion.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialOur bulk RNA-seq data is not from clinical trialFunding StatementNational Natural Science Foundation of China (Grant No.81872290, 81972172, and 81772763),the Shanghai Science and Technology Committee (No. 19XD1423200, 18140903900).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethics Committee of Shanghai Pulmonary HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe RNA-seq data is depositing in Genome Sequence Achive (GSA) of National Genomics Data center (NGDC). All the data will be available in the manuscript or from the authors upon request